PL90318B1 - - Google Patents

Download PDF

Info

Publication number
PL90318B1
PL90318B1 PL1973160769A PL16076973A PL90318B1 PL 90318 B1 PL90318 B1 PL 90318B1 PL 1973160769 A PL1973160769 A PL 1973160769A PL 16076973 A PL16076973 A PL 16076973A PL 90318 B1 PL90318 B1 PL 90318B1
Authority
PL
Poland
Prior art keywords
peptide
fatty acid
corticotropin
suspended
salt
Prior art date
Application number
PL1973160769A
Other languages
English (en)
Polish (pl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH229972A external-priority patent/CH574247A5/de
Application filed filed Critical
Publication of PL90318B1 publication Critical patent/PL90318B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35Corticotropin [ACTH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL1973160769A 1972-02-17 1973-02-15 PL90318B1 (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229972A CH574247A5 (en) 1972-02-17 1972-02-17 Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
CH1782972 1972-12-07

Publications (1)

Publication Number Publication Date
PL90318B1 true PL90318B1 (enEXAMPLES) 1977-01-31

Family

ID=25690055

Family Applications (1)

Application Number Title Priority Date Filing Date
PL1973160769A PL90318B1 (enEXAMPLES) 1972-02-17 1973-02-15

Country Status (18)

Country Link
US (1) US3869549A (enEXAMPLES)
JP (1) JPS4892516A (enEXAMPLES)
AR (1) AR197116A1 (enEXAMPLES)
AT (1) AT335615B (enEXAMPLES)
AU (1) AU472655B2 (enEXAMPLES)
BE (1) BE795516A (enEXAMPLES)
CS (1) CS172967B2 (enEXAMPLES)
DD (1) DD102584A5 (enEXAMPLES)
DE (1) DE2306075A1 (enEXAMPLES)
DK (1) DK134098B (enEXAMPLES)
ES (1) ES411655A1 (enEXAMPLES)
FR (1) FR2181734B1 (enEXAMPLES)
GB (1) GB1418408A (enEXAMPLES)
IE (1) IE37151B1 (enEXAMPLES)
IL (1) IL41416A (enEXAMPLES)
NL (1) NL7300953A (enEXAMPLES)
PL (1) PL90318B1 (enEXAMPLES)
SE (1) SE7600435L (enEXAMPLES)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254061A1 (de) * 1972-11-04 1974-05-16 Hoechst Ag Lh-releasing hormon zur nasalen applikation
DE2254043C2 (de) * 1972-11-04 1985-01-24 Hoechst Ag, 6230 Frankfurt LH-Releasing Hormon zur nasalen Applikation
JPS528375B2 (enEXAMPLES) * 1973-07-02 1977-03-09
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
DE3502099A1 (de) * 1985-01-23 1986-08-07 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
US4804742A (en) * 1985-06-06 1989-02-14 Rorer Pharmaceutical Corporation Amide analogs of calcitonin
US4650854A (en) * 1985-06-06 1987-03-17 Usv Pharmaceutical Corporation Amide analogs of calcitonin
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
IL79765A (en) * 1985-08-23 1992-02-16 Lilly Co Eli Injectable sustained release formulations of bovine somatotropin
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
KR19990071255A (ko) 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3253401B1 (en) 2015-02-03 2025-04-02 Amryt Endo, Inc. Treating acromegaly with oral octreotide
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
JP7077237B2 (ja) 2016-05-16 2022-05-30 インターシア セラピューティクス,インコーポレイティド グルカゴン受容体選択的ポリペプチド及びその使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer
US2944940A (en) * 1956-01-16 1960-07-12 Armour & Co Adrenocorticotrophin and zinc composition
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making

Also Published As

Publication number Publication date
DE2306075A1 (de) 1973-08-23
AR197116A1 (es) 1974-03-15
FR2181734A1 (enEXAMPLES) 1973-12-07
AU472655B2 (en) 1976-06-03
DD102584A5 (enEXAMPLES) 1973-12-20
DK134098C (enEXAMPLES) 1977-02-21
IL41416A0 (en) 1973-03-30
AT335615B (de) 1977-03-25
BE795516A (fr) 1973-08-16
DK134098B (da) 1976-09-13
AU5218973A (en) 1974-08-15
US3869549A (en) 1975-03-04
NL7300953A (enEXAMPLES) 1973-08-21
SE7600435L (sv) 1976-01-16
ES411655A1 (es) 1976-09-01
IL41416A (en) 1976-03-31
CS172967B2 (enEXAMPLES) 1977-01-28
IE37151L (en) 1973-08-17
ATA140873A (de) 1976-07-15
IE37151B1 (en) 1977-05-11
JPS4892516A (enEXAMPLES) 1973-11-30
GB1418408A (en) 1975-12-17
FR2181734B1 (enEXAMPLES) 1975-10-10

Similar Documents

Publication Publication Date Title
PL90318B1 (enEXAMPLES)
RU2201248C2 (ru) Стабильный водный пептидный препарат, способ его получения и способ лечения гормонзависимого заболевания у субъекта
DE69738300T2 (de) Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten
AU2003235401B2 (en) Medicinal compositions containing ghrelin
US4476116A (en) Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
DE69432224T2 (de) Aerosole als darreichungsform mit cfc-freiem treibmittel
RU2203085C2 (ru) Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта
FI95202C (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
EP3102184B1 (en) Stable peptide formulations and methods for preparation
EP1404357B1 (en) Gonadotropin releasing hormone antagonist in gel-forming concentrations
US6719992B2 (en) Non-aqueous surfactant-containing formulations for extended release of somatotropin
SI9300468A (en) Injectable composition for the sustained release of biologically active compounds
JPH10508294A (ja) 薬用組成物からのペプチドの持続的放出
HU218281B (en) Process for producing cetrorelix acetate liophylizate and pharmaceutical composition containing them
KR100633280B1 (ko) 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
JP2025004006A (ja) テベレリクス-tfa組成物
IE43770B1 (en) Calcitonin peptide preparations with prolonged action
US6719990B2 (en) Non-aqueous injectable formulations for extended release of somatotropin
DE2306074A1 (de) Neue salze von acth-peptiden und verfahren zu ihrer herstellung
CH574247A5 (en) Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
DE3915317A1 (de) Verwendung von gonadoliberinderivaten
KR20070021331A (ko) 약학적 활성 펩티드로 치료할 수 있는 증상을치료하기 위한 약학적 조성물 및 포장 제형
SA01210722B1 (ar) تكوين صيدلي يحتوي على فولفسترانت fulvestrant